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Abstract
Background: The aim of the present study was to analyze the expression of Zinc finger E-box Binding homeobox 2 (ZEB2) in
glioma and to explore the molecular mechanisms of ZEB2 that regulate cell proliferation, migration, invasion, and apoptosis.
Methodology/Principal Findings: Expression of ZEB2 in 90 clinicopathologically characterized glioma patients was analyzed
by immunohistochemistry. Furthermore, siRNA targeting ZEB2 was transfected into U251 and U87 glioma cell lines in vitro
and proliferation, migration, invasion, and apoptosis were examined separately by MTT assay, Transwell chamber assay, flow
cytometry, and western blot.
Results: The expression level of ZEB2 protein was significantly increased in glioma tissues compared to normal brain tissues
(P,0.001). In addition, high levels of ZEB2 protein were positively correlated with pathology grade classification (P=0.024)
of glioma patients. Knockdown of ZEB2 by siRNA suppressed cell proliferation, migration and invasion, as well as induced
cell apoptosis in glioma cells. Furthermore, ZEB2 downregulation was accompanied by decreased expression of CDK4/6,
Cyclin D1, Cyclin E, E2F1, and c-myc, while p15 and p21 were upregulated. Lowered expression of ZEB2 enhanced E-
cadherin levels but also inhibited b-Catenin, Vimentin, N-cadherin, and Snail expression. Several apoptosis-related regulators
such as Caspase-3, Caspase-6, Caspase-9, and Cleaved-PARP were activated while PARP was inhibited after ZEB2 siRNA
treatment.
Conclusion: Overexpression of ZEB2 is an unfavorable factor that may facilitate glioma progression. Knockdown ZEB2
expression by siRNA suppressed cell proliferation, migration, invasion and promoted cell apoptosis in glioma cells.
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Introduction
Despite the fact that glioma is one of the most common
primary brain tumors [1], surgery followed by chemotherapy
remain the standard treatment [2,3]. Unfortunately most
malignant gliomas are resistant to chemotherapeutic agents
and patients have a mean survival of 12 months after diagnosis
[4]. The aggressive nature of glioma is attributed to intense cell
proliferation, diffuse infiltration, and high resistance to apoptosis
[5,6], yet the factors that mediate glioma invasion and
recurrence are still poorly understood. Therefore, there is an
urgent need to identify critical carcinogenic pathways and
discover new therapeutic targets for glioma [7].
ZEB2 (also known as SIP1) is a member of the Zfh1 family of 2-
handed zinc finger/homeodomain proteins. The relevance of
ZEB2 to tumor progression has been studied in several forms of
human cancer and it has been associated with various clinico-
pathological features such as histological type, differentiation
grade, and overall survival [8,9,10]. Recent reports highlighted
that ZEB2 targeted by the miR-200 family [11,12,13] was closely
related to Epithelial-to-Mesenchymal Transition (EMT), suggest-
ing ZEB2 is a key factor in promoting the initiation and
development of tumors.
In this study, we evaluated the expression of ZEB2 in human
patient samples. Further, to explore its associated molecular
mechanisms in glioma cells, we examined the effect of targeted
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38842silencing of ZEB2 gene on cell proliferation, EMT, and cell
apoptosis using siRNA in vitro. These findings will be useful in
identifying potential candidates for targeted therapeutic interven-
tion of glioma.
Results
Immunohistochemical Analysis of ZEB2 Protein
Expression in Glioma and Normal Brain Tissues
Expression levels and subcellular localization of ZEB2 protein
was measured in 90 archived paraffin-embedded glioma samples
and 10 normal brain tissues using immunohistochemical staining
(Figure 1A–F). ZEB2 was highly expressed in 65.6% (59/90) of
glioma samples compared to only 20.0% (2/10) of normal brain
samples, which was a statistically significant difference (P,0.001)
(Table 1).
The relationship between clinicopathologic characteristics and
ZEB2 expression in individuals with glioma are summarized in
Table 2. No significant association between ZEB2 expression
levels and patient’s age or sex was observed in any of the 90 glioma
cases. However, we observed that the expression of ZEB2 was
positively correlated with the status of pathology classification
(WHO I-II vs. WHO III-IV) (P=0.024) in glioma patients
(Table 2).
Downregulation of ZEB2 Inhibits Glioma Cell
Proliferation, Migration and Invasion in U251 and U87
Cells
To explore the role of ZEB2 in glioma we utilized two human
cell lines established from high-grade tumors (U251 and U87
cells). Transcriptional levels of ZEB2, as assessed by RT-PCR,
Figure 1. Expression of ZEB2 in glioma and normal brain tissues. A and B. Weak expression of ZEB2 in normal brain tissues. C. Weak
expression of ZEB2 in glioma samples. D. Medium expression of ZEB2 in glioma samples. E and F. Strong staining of ZEB2 in glioma samples.
(Original magnification 4006).
doi:10.1371/journal.pone.0038842.g001
Table 1. Protein expression of ZEB2 between glioma and
normal brain tissues.
Group Protein expression P value
Cases High expression
Low
expression
cancer 90 59 31
normal 10 2 8 0.000
doi:10.1371/journal.pone.0038842.t001
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U251 cells and U87 cells compared to the negative control (si-NC
treated) groups respectively (P,0.05) (Figure 2A). Consistent
results for protein levels were observed by western blot (Figure 2B)
and immunofluorescence at 48 hr (Figure 2C).
The growth curves determined by MTT assay showed that
downregulation of ZEB2 significantly inhibited cell proliferation of
these two cell lines (Figure 3A). To examine the effect of ZEB2 on
cell migration, siZEB2-transfected U251 and U87 cells were
cultured on transwell apparatus. After 8 hr incubation, the
percentage of migrated cells was significantly less in both
siZEB2-treated groups (for both P,0.05) (Figure 3B). Using
a boyden chamber coated with matrigel, we determined changes
in cell invasiveness after 8 hr incubation. When compared with the
negative control groups, siZEB2-transfected U251 and U87 cells
both exhibited significantly decreased invasiveness (both P,0.05)
(Figure 3C).
ZEB2 Downregulation Promotes Expression of E-cadherin
but Suppresses EMT Progression in Glioma Cells
Examination of the protein levels indicated that E-cadherin was
significantly upregulated after siZEB2 transfection in both lines
(Figure 4). Similarly, the expression of EMT-related regulators,
such as N-Cadherin, Vimentin, b-Catenin and Snail were
decreased after ZEB2 knockdown (Figure 4). By immunofluores-
cence U251 and U87 cells exhibited high expression levels of b-
Catenin and Vimentin. The fluorescence intensity indicated
a significant decrease in the b-Catenin and Vimentin expression
and increase in the E-cadherin expression after 48 hr siZEB2
treatment (Figure 5).
Downregulation of ZEB2 Expression Induces Cell Cycle
Arrest at G1/S Phase by Regulating Cell Cycle-related
Genes in vitro
To study the link between cell cycle control and ZEB2 in glioma
cells, we first assessed the cell cycle distribution by flow cytometry
at 48 hr post transfection between negative control or siZEB2
treated cells. As shown in Figure 6A, cells exhibited a significant
increase in the cell fraction in G1 phase (U251-NC 45.5062.41%,
U251-siZEB2 59.2062.35%, U87-NC 45.3762.33%, U87-si-
ZEB2 65.0662.88%, P,0.05) and a corresponding reduction in
the fraction of cells in S phase (U251-NC 44.8362.52%, U251-
siZEB2 28.4060.93%, U87-NC 46.3561.20%, U87-siZEB2
23.37.0662.17%, P,0.05), while the percentage of cells in G2-
M phase was unaffected by ZEB2 inhibition.
To further study the mechanism by which ZEB2 regulates cell
cycle, we examined the protein levels of several key regulators of
cell cycle progression. CDK4 and E2F1 protein levels were
decreased in siZEB2-treated both for U251 and U87 cells.
However, compared to negative control groups, p21 protein levels
only increased in U251 cells but not in U87 cells, while the
expression of P15 was increased in U87 cells but not in U251 cells
at 72 hr post transfection (Figure 6B–C). Additionally, CDK6, p-
Rb, and Cyclin D1 were decreased in siZEB2 treated U251 while
c-myc and Cyclin E decreased in U87 cells. The expression levels
of other significant cell cycle regulators including p27, p16 were
unaffected after ZEB2 knockdown (Figure S1).
ZEB2 Downregulation Induces Apoptosis by the
Activation of Caspase-3 in Glioma Cells
The rate of cellular apoptosis in U251 and U87 cells was
examined using flow cytometric analysis with Annexin V staining.
The cellular apoptosis rate of U251 cells was 21.6362.10% in
siZEB2-treated and 4.0361.45% in negative control at 48 hr post
transfection. In U87 cells, apoptotic rates were 5.4960.79% in
untransfected controls, while 12.5361.86% in siZEB2-treated
(Figure 7A). Thus, downregulation of ZEB2 significantly induced
apoptosis in both the U251 and U87 cells. We next assessed the
mechanism by which ZEB2 regulates apoptosis. Using western
blot analysis, we found that Caspase-3, Caspase-6, Caspase-9 and
Cleaved-PARP protein levels increased while PARP protein
decreased in both siZEB2 treated U251 and U87 cells compared
to negative controls (Figure 7B).
Discussion
The expression of ZEB2 has been reported in different tumors
[8,9,10]. Elevated expression of ZEB2 is associated with degree of
malignancy, rapid cell proliferation, and poor patient survival in
different tumors [8,9,14], suggesting that ZEB2 expression may
have significant value as a biomarker in glioma patients.
In the present study, we firstly confirmed that ZEB2 mRNA
levels were higher in glioma samples than that in normal brain
tissues (Figure S2). Further, we found that ZEB2 was mainly
localized in the nucleus and cytoplasm of glioma tissues while
predominantly weakly expressed in cytoplasm in normal brain
tissues by immunohistochemistry. Consistent with mRNA levels,
ZEB2 protein expression was significantly elevated in glioma
samples compared to normal brain tissues. Furthermore, we also
observed that the expression level of ZEB2 was positively
correlated with tumor grading as there was a significant difference
between high and low grade gliomas. These data strongly imply an
oncogenic role of ZEB2 in glioma tumorigenesis.
The biological functions of ZEB2 found in this study provided
a mechanistic basis for the pathological and clinical observations.
In agreement with a previous study [15], we found that
knockdown of ZEB2 expression inhibited cell proliferation,
migration, and invasion of glioma cells. However, there is little
knowledge of the relationship between ZEB2 and cell cycle
progression or apoptosis in glioma cells. In our study, we
demonstrated that high ZEB2 expression not only regulated
EMT, but also mediated the cell cycle progression and apoptosis in
glioma cell lines.
Table 2. Correlation between the clinicopathologic
characteristics and expression of ZEB2 protein in glioma.
ZEB2(%)
Characteristics n
High-
expression
Low-
expression P
Gender
Male 53 36(67.9%) 17(32.1%)
Female 37 23(62.2%) 14(37.8%) 0.571
Age
$50 48 32(66.7%) 16(33.3%)
,50 42 27(64.3%) 15(35.7%) 0.813
WHO Grade
I 10 4(40.0%) 6(60.0%)
II 25 14(56.0%) 11(44.0%)
III 26 18(69.3%) 8(30.7%)
IV 29 23(79.3%) 6(20.7%) 0.024
doi:10.1371/journal.pone.0038842.t002
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phenotype indicative of EMT [16], and is involved in cell
migration and invasion which are key steps in the progression of
glioma [17]. The loss of E-cadherin and overexpression of
mesenchymal cell markers such as N-cadherin, Vimentin are
hallmarks of EMT [18]. Consistent with Xia et al’s report [15],
our data indicated that knockdown of ZEB2 resulted in restoration
of E-cadherin expression and suppression of Vimentin expression
in glioma cells. Furthermore, we observed that ZEB2 down-
regulation also inhibited the expression of other mesenchymal cell
markers such as N-Cadherin, b-Catenin and transcription factor
Snail.
ZEB2 regulation of cell growth has been reported through cell
colony formation assays in glioma [15]. In this study, we also
observed that lost expression of ZEB2 reduced cell proliferation
using an MTT assay. Decreased expression of ZEB2 reduced the
Figure 2. Effect of siRNA interference on ZEB2 expression in human glioma cell lines U251 and U87. Different treatments included
negative control (NC) and siZEB2-transfected groups (siZEB2). A. RT-PCR shows transcriptional levels of the ZEB2 gene 48 hr post transfection and
ARF was used as a loading control. The arbitrary units were plotted using mean 6 SD of at least three individual repetitions. B. Western blot showing
protein expression levels in NC and siZEB2 treatments. At 72 hr post transfection, cells were harvested and whole cell lysates prepared using RIPA
buffer. The representative image of three different repetitions is shown. b-actin served as a loading control. Bar graph shows the relative expression
of protein among the groups. Data are presented as mean 6 SD for three independent experiments. C. Immunofluorescence study using blinded
analysis showing the expression of ZEB2 in NC and siZEB2-treated U251 and U87 cells at 48 hr post-transfection (Original magnification 10006).
*P,0.05, statistically significant difference.
doi:10.1371/journal.pone.0038842.g002
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progression from G1 to S phase, while the percentage of cells in
G2-M phase was unaffected by ZEB2 inhibition. This might be
partly attributed to the suppressive effect of ZEB2 on cell cycle
progression. This process is partly dependent on the tightly
regulated activity of Cyclin dependent kinases (CDKs). Cyclin D/
CDK4/6 activity occurs in mid-late G1 phase, upstream of
CDK2/Cyclin E activity. Both of these pathways are required for
hyperphosphorylation of the retinoblastoma gene product (pRb)
[14]. One of the cell cycle regulatory pathways most often affected
in cancer is the G1 checkpoint, which is controlled by a complex
network of Cyclin D, CDKs, Rb and Rb-related proteins. E2F1 is
a key downstream target of pRb [19]. There is a significant
correlation between high levels of E2F1 protein and high-grade
Figure 3. Downregulation of ZEB2 inhibits glioma cell proliferation, migration and invasion in vitro. A. Effect of ZEB2 knockdown on
U251 and U87 cell proliferation as measured by MTT assay. Absorbance was read at 490 nm with averages from triplicate wells. B and C.
Downregulation of ZEB2 dramatically reduced U251 and U87 cell migration and invasion in vitro. Data are presented as mean 6 SD for three
independent experiments (Original magnification 4006). *P,0.05, statistically significant difference.
doi:10.1371/journal.pone.0038842.g003
Figure 4. ZEB2 downregulation promotes expression of E-cadherin but suppresses EMT progression in glioma cells. ZEB2 reduction
enhanced expression of E-cadherin and expression level changes of N-cadherin, Snail, b-Catenin and Vimentin in U251 and U87 cells at 72 hr post-
transfection. b-actin was used as a loading control. Bar graph shows the relative expression of protein among the groups. Data are presented were
presented as mean 6 SD for three independent experiments. *P,0.05, statistically significant difference.
doi:10.1371/journal.pone.0038842.g004
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transition [21,22]. Increased expression of c-myc is associated with
neoplastic transformation and angiogenesis in glioma [23,24]. In
this investigation, we found that the downregulation of ZEB2 by
siRNA induced increases of p21 in U251 cells and p15 in U87
cells. Meanwhile, siZEB2 decreased CDK4/6, Cyclin D1, E2F1
protein levels U251 cell, and CDK4, Cyclin E, E2F1 and c-myc in
U87 cells. These results are partially consistent with Yang et al’s
report [20]. The changes of CDK4/6 and p21 mediated by ZEB2
knockdown in the U251 glioma cell line suggest potential avenues
to target these proteins in tumors. Similarly, in U87 cells, c-myc,
Cyclin E, and p15 protein expression were mediated by ZEB2.
Because of the difference sources of U251 [25] and U87 [26] cell
lines, we considered that siZEB2 treatment induced cell cycle
arrest at G1/S phase through different pathways, and this may be
dependent on tumor types. Interestingly, the expression levels of
other significant cell cycle regulators including p27 and p16 did
not change after ZEB2 knockdown which suggests similar
regulatory effects on the cell cycle machinery mediated by ZEB2
in glioma cells.
Apoptosis is a well-orchestrated cellular mechanism that
balances cell proliferation and cell death. Recent evidence
indicates that ZEB transcription factors may also regulate
apoptosis and senescence separately from regulation of EMT
[27,28,29]. DNA breakage and activation of DNA damage
response often leads to apoptosis or senescence. PARP is activated
during DNA strand break repair [30,31], and has been previously
demonstrated to be requiremed for DNA damage-induced NF-kB
[32]. Inhibition of PARP degradation leads to persistent NF-kB
DNA binding, increased anti-apoptotic gene expression and
a protection against cell death [33]. Our data indicate that
reduced expression of ZEB2 significantly induced apoptotic cell
death in both the U251 and U87 cells. In corroboration with these
results, siZEB2 treatment resulted in the elevation of Cleaved-
PARP, Caspase-3, Caspase-6, and Caspase-9 as well as reduced
PARP levels in U251 and U87 cells.
Figure 5. Immunofluorescence of EMT related regulators in NC and siZEB2-treated U251 and U87 cells at 48 hr post-transfection.
High expression of b-Catenin and Vimentin and low E-cadherin expression in U251 and U87 cells was observed. After transfection with siZEB2 in both
glioma cell lines, the expression of b-Catenin and Vimentin were decreased while E-cadherin was increased. (Original magnification 4006).
doi:10.1371/journal.pone.0038842.g005
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38842Figure 6. Downregulation of ZEB2 expression induced cell cycle arrest at G1/S phase by regulating cell cycle-related genes. A. The
cell cycle distribution in siZEB2 treated and NC groups of U251 and U87 glioma cells by FACS Caliber cytometry. Histograms showing G1/S phase
arrest and a decline in S phase in U251 and U87 cells after knocking down ZEB2 expression through targeted siRNA transfection. B and C. The
protein levels of several key cell cycle regulators was analyzed by western blot. Reduced ZEB2 expression significantly inhibited cell cycle progression
in U251 and U87 glioma cells. b-actin was used as a loading control. Bar graph shows the relative expression of protein among the groups. Data are
presented were presented as mean 6 SD for three independent experiments. *P,0.05, statistically significant difference.
doi:10.1371/journal.pone.0038842.g006
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38842We hypothesize that ZEB2 regulates cell cycle progression,
migration, invasion, and apoptosis in glioma through at least two
molecular mechanisms. ZEB2 may contribute to tumor pro-
gression by protecting cancer cells from apoptosis and DNA
damage by activating NF-kB, which can prevent cell death in
glioma [34] and result in downregulation of E-cadherin mediated
classical EMT [35]. Meanwhile, repressed expression of Caspase-
3, -6, -9 and enforced expression of PARP from ZEB2 can
enhance DNA repair and cell cycle progression. ZEB2 may also
function as a transcriptional promoter as shown for the Smad-
dependent TGF-b signaling pathway [36,37], ZEB2 may also
reduce expression of the cell cycle inhibitors p15 and p21, and
promote G1 to S phase cell cycle progression by mediating the
activity of CDK4/6, Cyclin D1, and Cyclin E, which will
eventually result in hyperphosphorylation of RB, releases of E2F1
and overexpression of the mitogenic transcription factor c-myc.
In summary, ZEB2 expression may have significant value as an
unfavorable progression indicator for glioma patients. We provide
compelling evidence that decreased expression of ZEB2 inhibits
cell proliferation, migration, invasion, and induces cell death
through multiple pathways involving in cell cycle, apoptosis, and
EMT.
Figure 7. ZEB2 downregulation induces apoptosis by the activation of Caspase-3 in glioma cells. A. Apoptosis in U251 and U87 cells was
measured by Annexin V-FITC/propidium iodide (PI) staining following siZEB2 or control treatment. Early apoptotic cell populations were significantly
increased (P,0.01) after siZEB2 transfection. B. Western blot analysis for antiapoptotic PARP and effector Caspase-3, Caspase-6 and Caspase-9.
Decreased PARP and increased caspase-3,-6,-9, and Cleaved PARP expression were observed in U251 and U87 cells after ZEB2 downregulation at
72 hr post transfection. b-actin was used as a loading control. Bar graph shows the relative expression of protein among the groups. Data are
presented were presented as mean 6 SD for three independent experiments. *P,0.05, statistically significant difference.
doi:10.1371/journal.pone.0038842.g007
ZEB2 in Glioma
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38842Materials and Methods
Sample Collection
Ten fresh normal brain tissues sample and ten glioma samples
were collected from the Nanfang Hospital of Southern Medical
University, Guangzhou, China, at the time of diagnosis before any
therapy. All fresh samples were immediately preserved in liquid
nitrogen. Ninety archived paraffin-embedded glioma and 10
normal brain tissues samples were obtained from the Nanfang
Hospital of Southern Medical University, Guangzhou, China.
These cases were from 53 males and 37 females with age ranging
from 13 to 68 years (median 42.1 years). All specimens had
confirmed pathological diagnosis and were classified according to
the World Health Organization (WHO) criteria.
Ethics Statement
For the use of these clinical materials for research purposes,
there were 3 children participants involved in our study, and we
obtained written informed consent from their guardians or next of
kin. We obtained all written informed consent from adult patients
directly. Prior consents from all patients and approval from the
Ethics Committees of Nanfang Hospital were obtained.
Immunohistochemistry Staining
The details of immunohistochemistry methods were used as
described previously [38]. The anti-human ZEB2 antibody (1:150)
(Bioworld, Inc,USA) was used. The immunohistochemically
stained tissue sections were reviewed and scored separately by
two pathologists blinded to the clinical parameters. Expression of
ZEB2 in the nucleus and in the cytoplasm was independently
evaluated. For cytoplasmic staining, the score was evaluated
according to the sum of cytoplasm staining intensity and the
percentage of positive staining areas of cells. The staining intensity
was scored as previously described [38](Materials & Methods S1).
Cell Culture
The human glioma cell lines U251 and U87 were purchased
from the Chinese Academy of Sciences (Shanghai, China) and
grown in Dulbecco’s modified Eagle’s medium (DMEM) (Hy-
clone, Logan, UT) supplemented with 10% fetal calf serum
(ExCell, Shanghai, China). All cell lines were cultured at 37uCi n
a humidified atmosphere of 5% CO2.
RNA Isolation and Detection of ZEB2 mRNA Levels by
Real-time PCR
Total RNA from fresh ten normal brain tissues sample, ten
glioma samples and glioma cells was isolated by using Trizol
reagent (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. The ImProm-II Reverse Transcription kit
(Promega Corporation, Madison, WI) along with 2 mg of total
RNA and poly-dT primers were used for synthesis of cDNA. To
determine the RNA transcript levels from cDNA, Real-time PCR
was carried out using a MX3000P instrument (Stratagene, La
Jolla, CA, USA) and SYBRH Premix Ex Taq
TM kit (Takara, Otsu,
Japan) as described previously [39] to detect the mRNA level of
ZEB2. The sequence for sense primer was 59-GGCGCAAA-
CAAGCCAATCCCA-39, and for antisense primer was 59-
TTCACTGGACCATCTACAGAGGCTT-39. ARF gene was
used as an internal control using the sense primer 59-
ATCTGTTTCACAGTCTGGGACG-39 and antisense primer
59-CCTGCTTGTTGGCAAATACC-39. PCR cycling conditions
were 95uC for 10 min to activate DNA polymerase, followed by 45
cycles of 95uC for 15 s, 55uC for 15 s, and 72uC for 10 s.
Specificity of amplification products was confirmed by melting
curve analysis. Independent experiments were done in triplicate.
Transient Transfection with siRNAs
Small-interfering RNA (siRNA) were designed and synthesized
by Guangzhou RiboBio (RiboBio Inc, China). Three siRNAs
targeting on ZEB2 gene were designed and synthesized, the most
effective siRNA (siZEB2) identified by Real Time-PCR was
applied for the further experiments. The sequence of siZEB2 is:
sense: 59- GGACACAGGUUCUGAAACA dTdT-39; anti-sense:
39- dTdT CCUGUGUCCAAGACUUUGU-59. The sequence of
si-negative control (si-NC) was also designed by RiboBio (RiboBio
Inc, China). Twenty-four hours prior to transfection, U251 or U87
cells were plated onto a 6-well plate or a 96-well plate (Nest,
Biotech,China) at 40–60% confluence. Cells were then transfected
by incubation with siZEB2 (si-NC as a control) at final
concentrations of 50 nM with TurboFectTM siRNA Transfection
Reagent (Fermentas). The medium was not replaced after
transfection according to the manufacturer’s protocol. Cells were
collected after 48 hr for the following assays or after 72 hr for
RNA and protein extraction (Figure S3).
Cell viability and Proliferation Assay
Cell proliferation was analyzed using 3-(4,5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were
seeded in 96-well plates at a density of 700 cells/well. The cells
were incubated for 1, 2 or 3 days. Twenty microliters of MTT
(5 mg/ml) (Sigma, St. Louis, MO) was added to each well and
incubated for 4 hr. At the end of incubation, the supernatants
were removed, and 150 ml of DMSO (dimethyl sulfoxide) (Sigma,
St. Louis, MO) was added to each well. The absorbance value
(OD) of each well was measured at 490 nm. For each experimen-
tal condition, eight wells were used. Experiments were performed
thrice.
Cell migration and Invasion Assays
For cell migration assays, 1610
4 cells in 100 ml DMEM
medium without FCS were seeded on a fibronectincoated
polycarbonate membrane insert in a transwell apparatus (Costar,
MA). In the lower chamber, 600 ml DMEM with 10% FCS was
added as a chemoattractant. After the cells were incubated for 8 hr
at 37uC in a 5% CO2 atmosphere, the insert was washed with
PBS, and cells on the top surface of the insert were removed with
a cotton swab. Cells adhering to the lower surface were fixed with
methanol, stained with Giemsa solution and counted under
a microscope in five predetermined fields (2006). All assays were
independently repeated at least thrice.
For cell invasion assays, the procedure was similar to the cell
migration assay, except transwell membranes were precoated with
24 mg/ml Matrigel (R&D Systems, USA) and the cells were
incubated for 8 hr at 37uC in a 5% CO2 atmosphere. Cells
adhering to the lower surface were counted the same way as the
cell migration assay.
Cell Cycle Analysis
For cell cycle analysis, cells were seeded on 10-cm–diameter
plates in DMEM containing 10% FCS. After incubation for 48 hr,
a total of 5610
6 cells were harvested, rinsed with cold PBS and
fixed with 70% ice-cold ethanol for 48 hr at 4uC. Fixed cells were
rinsed with cold PBS followed by incubation with PBS containing
10 mg/ml propidium iodide and 0.5 mg/ml RNase A for 15 min
at 37uC. The DNA content of labeled cells was acquired using
ZEB2 in Glioma
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was performed in triplicate.
Apoptosis Assay
Apoptosis was measured by using an Annexin V/fluorescein
isothiocyanate (FITC) apoptosis detection kit (Keygen, China).
Briefly, cells cultured in 6-cm dishes were trypsinized, washed,
stained with FITC-conjugated anti-Annexin V antibody under
darkness for 15 min at room temperature, and then analyzed by
flow cytometry (BD Biosciences). Each experiment was performed
in triplicate.
Immunofluorescence
U251 and U87 cells were seeded on coverslips in 6-well plate
and cultured overnight. Subsequently cells were fixed in 3.5%
paraformaldehyde, permeabilized in KB solution and 0.2% Triton
X-100 at room temperature. After the blocking solution was
removed, cells were incubated with a primary antibody (diluted in
KB) 30–45 min at 37uC and subsequently washed with KB twice.
After incubating 30–45 min at 37uC with secondary antibody
(diluted in KB), cells were washed with KB again, then mounted
onto slide with mounting solution containing 0.2 mg/ml DAPI and
seal with nail polisher. Slides were stored at 4uC in a dark box and
observed under a fluorescent microscope.
Western Blot Analysis
Cells were lysed in RIPA Buffer (50 mM Tris-HCl pH 8.0,
1 mM EDTA pH 8.0, 5 mM DTT, 2% SDS), and protein
concentration was determined by using BCA assay (Beyotime Inc,
China). Total protein (30 mg) was resolved using a 10% SDS-
PAGE gel and electro-transferred to polyvinylidene fluoride
membranes (Invitrogen, Carlsbad, CA), and blocked with 5%
nonfat dry milk in Tris-buffered saline, pH 7.5. Membranes were
immunoblotted overnight at 4uC (Materials & Methods S2).
Statistical Analysis
All quantified data represented an average of at least triplicate
samples or as indicated. SPSS 13.0 and Graph Pad Prism 4.0
software were used for statistical analysis. Data are represented as
mean 6 S.E.M. One-way ANOVA or two-tailed Student’s t-test
was used for comparisons between groups. Chi-square test or
Fischer’s were used to identify differences between categorical
variables. Differences were considered statistically significant when
P,0.05.
Supporting Information
Figure S1 The protein expression levels of some key cell cycle-
related genes after knockdown of ZEB2 in glioma cells. The
protein levels of several key regulators of cell cycle was analyzed by
western blotting. In U251 cells, the expression levels of p27, p16,
p15, Cyclin E, c-myc were not significantly differences between
the siZEB2 treated groups and the NC groups. Similarly, the
expression levels of some cell cycle-related genes, such as CDK6,
p27, p21, p16, Cyclin D1, and p-Rb, were not significantly
differences between the siZEB2 and NC groups in U87 glioma
cells. b-actin is used as a loading control. *P,0.05, statistically
significant difference.
(TIF)
Figure S2 The mRNA levels of ZEB2 in normal brain tissues
and glioma samples. The mRNA levels of ZEB2 from ten normal
brain tissues sample and ten glioma samples were analyzed by RT-
PCR. Data showed that the mRNA levels of ZEB2 in glioma were
higher than that of normal brain tissues (0.857960.05737/
0.413160.05357). *P,0.05, statistically significant difference.
(TIF)
Figure S3 Effect of siRNA interference on ZEB2 expression in
human glioma cell lines U251 and U87 analyzed by Real-time
PCR. RT-PCR shows transcriptional levels of the ZEB2 gene after
transfection using three different RNAi targeted ZEB2, and ARF
was as a loading control. The sequence of siRNA-1 is: sense: 59-
GGACACAGGUUCUGAAACA dTdT-39; anti-sense: 39- dTdT
CCUGUGUCCAAGACUUUGU-59; The sequence of siRNA-2
is: sense: 59- CUGCAAGGCUGAAGAAAUU dTdT-39; anti-
sense: 39- dTdT GACGUUCCGACUUCUUUAA-59; The se-
quence of siRNA-3 is: sense: 59- CAAAUAAUCUGGACAACAA
dTdT-39; anti-sense: 39- dTdT GUUUAUUAGACCUGUU-
GUU-59. A. 24 h post-transfection in U251 cells. B. 48 h post-
transfection in U251 cells. C. 24 h post-transfection in U87 cells.
D. 48 h post-transfection in U87 cells. The arbitrary units were
plotted using mean 6 SE of at least three individual repetitions.
*P,0.05, statistically significant difference.
(TIF)
Materials & Methods S1 Evaluation of staining
(DOC)
Materials & Methods S2 Western blot
(DOC)
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